This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Czuczman, M. S. Articles by Hernandez-Ilizaliturri, F. J. Search for Related Content PubMed PubMed Citation Articles by Czuczman, M. S. Articles by Hernandez-Ilizaliturri, F. J.

Acquirement of Rituximab Resistance in Lymphoma Cell Lines Is Associated with Both Global CD20 Gene and Protein Down-Regulation Regulated at the Pretranscriptional and Posttranscriptional Levels

Authors' Affiliations: Departments of ¹ Medicine, ² Immunology, and ³ Molecular Diagnostics, Roswell Park Cancer Institute, Buffalo, New York and ⁴ University of Calgary, Calgary, Alberta, Canada

Requests for reprints: Myron S. Czuczman, Lymphoma/Myeloma Service, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263. Phone: 716-845-3221; E-mail: myron.czuczman{at}roswellpark.org.

Acquirement of resistance to rituximab has been observed in lymphoma patients. To define mechanisms associated with rituximab resistance, we developed various rituximab-resistant cell lines (RRCL) and studied changes in CD20 expression/structure, lipid raft domain (LRD) reorganization, calcium mobilization, antibody-dependent cellular cytotoxicity, and complement-mediated cytotoxicity (CMC) between parental and RRCL. Significant changes in surface CD20 antigen expression were shown in RRCL. Decreased calcium mobilization and redistribution of CD20 into LRD were found in RRCL. Western blotting identified a unique 35 kDa protein band in RRCL, which was not seen in parental cells and was secondary to an increase in surface and cytoplasmic expression of IgM light chains. CD20 gene expression was decreased in RRCL. In vitro exposure to PS341 increased CD20 expression in RRCL and minimally improved the sensitivity to rituximab-associated CMC. Our data strongly suggest that the acquisition of rituximab resistance is associated with global gene and protein down-regulation of the CD20 antigen affecting LRD organization and downstream signaling. CD20 expression seems to be regulated at the pretranscriptional and posttranscriptional levels. Proteasome inhibition partially reversed rituximab resistance, suggesting the existence of additional mediators of rituximab resistance. Future research is geared to identify drugs and/or biological agents that are effective against RRCL.

This article has been cited by other articles:

				J. L. Espinoza, H. Takamatsu, X. Lu, Z. Qi, and S. Nakao Anti-moesin antibodies derived from patients with aplastic anemia stimulate monocytic cells to secrete TNF-{alpha} through an ERK1/2-dependent pathway Int. Immunol., June 25, 2009; (2009) dxp058v1. [Abstract] [Full Text] [PDF]

				D. A. Thomas, S. O'Brien, J. L. Jorgensen, J. Cortes, S. Faderl, G. Garcia-Manero, S. Verstovsek, C. Koller, S. Pierce, Y. Huh, et al. Prognostic significance of CD20 expression in adults with de novo precursor B-lineage acute lymphoblastic leukemia Blood, June 18, 2009; 113(25): 6330 - 6337. [Abstract] [Full Text] [PDF]

				J. Hiraga, A. Tomita, T. Sugimoto, K. Shimada, M. Ito, S. Nakamura, H. Kiyoi, T. Kinoshita, and T. Naoe Down-regulation of CD20 expression in B-cell lymphoma cells after treatment with rituximab-containing combination chemotherapies: its prevalence and clinical significance Blood, May 14, 2009; 113(20): 4885 - 4893. [Abstract] [Full Text] [PDF]

				H.-P. Gerber, M. Kung-Sutherland, I. Stone, C. Morris-Tilden, J. Miyamoto, R. McCormick, S. C. Alley, N. Okeley, B. Hayes, F. J. Hernandez-Ilizaliturri, et al. Potent antitumor activity of the anti-CD19 auristatin antibody drug conjugate hBU12-vcMMAE against rituximab-sensitive and -resistant lymphomas Blood, April 30, 2009; 113(18): 4352 - 4361. [Abstract] [Full Text] [PDF]

				Y. Terui, Y. Mishima, N. Sugimura, K. Kojima, T. Sakurai, Y. Mishima, R. Kuniyoshi, A. Taniyama, M. Yokoyama, S. Sakajiri, et al. Identification of CD20 C-Terminal Deletion Mutations Associated with Loss of CD20 Expression in Non-Hodgkin's Lymphoma Clin. Cancer Res., April 1, 2009; 15(7): 2523 - 2530. [Abstract] [Full Text] [PDF]

				N. A. Johnson, S. Leach, B. Woolcock, R. J. deLeeuw, A. Bashashati, L. H. Sehn, J. M. Connors, M. Chhanabhai, A. Brooks-Wilson, and R. D. Gascoyne CD20 mutations involving the rituximab epitope are rare in diffuse large B-cell lymphomas and are not a significant cause of R-CHOP failure Haematologica, March 1, 2009; 94(3): 423 - 427. [Abstract] [Full Text] [PDF]

				S. Dalle, S. Dupire, S. Brunet-Manquat, L. Reslan, A. Plesa, and C. Dumontet In vivo Model of Follicular Lymphoma Resistant to Rituximab Clin. Cancer Res., February 1, 2009; 15(3): 851 - 857. [Abstract] [Full Text] [PDF]

				P.-C. Tsai, N. Bangia, S. Olejniczak, F. J. Hernandez-Ilizaliturri, and M. Czuczman The Acquirement of Rituximab Resistance Is Associated with a Global Downregulation of CD54 in B-Cell Lymphoma Cells: The Potential Role of Adhesion Molecules in Rituximab Anti-Tumor Activity Blood (ASH Annual Meeting Abstracts), November 16, 2008; 112(11): 2607 - 2607. [Abstract]

				C. Stolz, G. Hess, P. S. Hahnel, F. Grabellus, S. Hoffarth, K. W. Schmid, and M. Schuler Targeting Bcl-2 family proteins modulates the sensitivity of B-cell lymphoma to rituximab-induced apoptosis Blood, October 15, 2008; 112(8): 3312 - 3321. [Abstract] [Full Text] [PDF]